Dublin, Jan. 30, 2026 (GLOBE NEWSWIRE) -- The "Strategic Intelligence: Companion Diagnostics (2025)" report has been added to ResearchAndMarkets.com's offering.
Companion diagnostics (CDx) are medical devices, most commonly an in vitro diagnostic (IVD) that provides information necessary for the safe and effective use of a corresponding drug or biological product. CDx support the expansion of personalized medicine by assessing predictive biomarkers, such as genetic variation or protein expression, in individual patients to determine the most effective use of an associated therapy.
Scope
- Oncology is still the most common use for companion diagnostics, as they play a crucial role in the development of targeted therapies
- Companion diagnostics can be used to identify patients who are likely to benefit from a particular therapy
- There is potential for companion diagnostics to be applied in other therapy areas, such as rare diseases, neurological disorders and cardiovascular diseases.
Reasons to Buy
- Understand how companion diagnostics are evolving, the current uses and future potential.
- Understand the key players, the challengers, and product offerings.
- Understand key applications of companion diagnostics.
Key Topics Covered:
- Executive Summary
- Players
- Technology Briefing
- Trends
- Industry Analysis
- Value Chain
- Companies
- Sector Scorecard
- Glossary
For more information about this report visit https://www.researchandmarkets.com/r/eulii5
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
